An interventional study of Personalized Cardiac Rehabilitation Program in Cardiac Rehab and Coronary Artery Disease, sponsored by Kutahya Health Sciences University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Kutahya Health Sciences University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Coronary Artery Disease with a site in Turkey — 33 open to participants now, 42 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.
Among the 138 studies in Coronary Artery Disease with a site in Turkey, this one is the 60th largest by planned enrollment of the 72 interventional ones that give a count, is one of 25 that started in 2026, is one of 59 with no phase, reaches primary completion later than 19 of the 41 other live ones, and was the 132nd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →33 of the 138 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:
Adiyaman University · Sites in Turkey
Ages 18+
Elzem SEN · Sites in Turkey
Ages 18–80
Elzem SEN · Sites in Turkey
Ages 18–80
TC Erciyes University · Sites in Turkey
Ages 18–50 · Women only
Uludag University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 11 · Phase 4 1
First in 2004; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 70 across the 72 interventional studies, 167 across the 66 observational. Of the 83 that completed or were terminated, 10 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 138 have an industry lead sponsor. The 10 most frequent:
Kutahya Health Sciences University is the lead sponsor of 219 studies on the registry; 48 are open to participants now.
Kutahya Health Sciences University has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Coronary Artery Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07051473Istanbul University - CerrahpasaRelationship Between Coronary CT Angiography Findings and Prognosis Of Patients Undergoing PCI | 2026-12 |
| NCT07825376Abant Izzet Baysal UniversityBranching Scenario-Based Education in Coronary Artery Disease | 2026-12 |
| NCT07771127Uludag UniversityHEMOSTATİC PAD AND SANDBAG | 2026-12-30 |
| NCT07841847Kutahya Health Sciences UniversityEffects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 138 studies in Coronary Artery Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program.
Behavioral: Personalized Cardiac Rehabilitation Program
Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing.
Change in miRNA Expression Levels
Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Peak Oxygen Uptake (VO₂max)
Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Exercise Workload
Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Six-Minute Walk Test Distance
Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Resting Heart Rate
Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Heart Rate
Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Health-Related Quality of Life
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program.
Time frame: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Plan to share: No — "Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.
Of 754 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 3 months is below that.
Counting every sponsor, half of 931 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kutahya Health Sciences University →